Andreas Hoefer,Helena Seth-Smith,Federica Palma et al.
Andreas Hoefer et al.
Background: A surge of cases of Corynebacterium diphtheriae infection was observed in reception centers for migrants in Europe beginning in the summer of 2022. Most of the cases were cutaneous, although some respiratory c...
Aurore Perrot,Jérôme Lambert,Cyrille Hulin et al.
Aurore Perrot et al.
Background: Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell t...
Jecca R Steinberg
Jecca R Steinberg
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy [0.03%]
含铂化疗后的广泛期小细胞肺癌患者中Tisotumab Vedotin的疗效和安全性：随机、双盲、安慰剂对照III期EVOLVE试验的主要研究结果
Giannis Mountzios,Longhua Sun,Byoung Chul Cho et al.
Giannis Mountzios et al.
Background: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatama...
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer [0.03%]
口服选择性雌激素受体降解剂VERDELYS（vepredegestrant）治疗晚期乳腺癌：VEVANTE研究的1b/2期结果
Mario Campone,Michelino De Laurentiis,Komal Jhaveri et al.
Mario Campone et al.
Background: Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin-proteasome system. ...
Menopausal Symptom Management in Breast Cancer Survivors - A Promising New Option [0.03%]
乳腺癌幸存者绝经症状管理的新希望
Ann H Partridge
Ann H Partridge
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer [0.03%]
胃癌和胃食管结合部癌的围手术期德瓦鲁单抗治疗
Yelena Y Janjigian,Salah-Eddin Al-Batran,Zev A Wainberg et al.
Yelena Y Janjigian et al.
Background: Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain high. Immunothe...
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer [0.03%]
新辅助纳武单抗联合化疗治疗肺癌的总生存期
Patrick M Forde,Jonathan D Spicer,Mariano Provencio et al.
Patrick M Forde et al.
Background: Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non-small-cell lung cancer (NSCLC) in a phase 3 trial. Data are...
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer [0.03%]
PIK3CA突变的晚期乳腺癌患者使用Inavolisib治疗后的总生存期分析
Komal L Jhaveri,Seock-Ah Im,Cristina Saura et al.
Komal L Jhaveri et al.
Background: In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib-fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus palbociclib...
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma [0.03%]
高风险皮肤鳞状细胞癌的辅助Cemiplimab或安慰剂治疗
Danny Rischin,Sandro Porceddu,Fiona Day et al.
Danny Rischin et al.
Background: Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been well establi...